Buy now

Manufacturer

The history of Novartis traces back to three companies: Geigy, whose origins go back to the middle of the 18th century, Ciba, founded around 1859; and Sandoz, established in 1886. In 1970, Ciba and Geigy merged. The newly created Ciba-Geigy and Sandoz continued to follow separate path for two and a half decades. In 1996, Sandoz and Ciba-Geigy joined to form Novartis.

The name of Novartis that means from the Latin language "new achievements" indicates the main goal of corporation: to discover, develop and successfully promote new pharmaceutical preparations for treating diseases, relieving sufferings and prolongation of people's life. Novartis follows the principles of the business ethical conducting, social responsibility and protection of the environment.

Novartis is a global leader in innovative pharmaceuticals, generics, Rx and OTC medications. Novartis also covers the major parts of EU pharmaceutical market in vaccines, ophtalmologic and veterinary products. In 2002 the companies revenue reached 32,4 billions of swiss francs(CHF) and net profit amounted nearly 7.3 billions of CHF. Each year Novartis invests billion of CHF in scientific research and developments. The Novartis headquarter is situated in Basel, Switzerland. More than 73 thousands of people work in 140 countries where Novartis established its representations.

The medications manufactured by Novartis have made possible to transplant organs . Many of the Novartis drugs are successfully used in the treatment of Alzheimer's disease, rheumatoid arthritis, fungus diseases, hypertension, oncologic diseases, osteoporosis, Parkinson, schizophrenia, epilepsy, diabetes mellitus, bronchial asthma and many other possible illnesses.

For the Sindammun and Sindostatin discovery that are used in the transplantology and esophagus varix dilatation Novartis received Galen Award.

In 2007 Novartis was ranked No. 1 among pharmaceutical companies in Fortunes magazines's "World Most Admired Companies" survey.

In 1996 Novartis put on sale new generation of angiotensin II receptor blockers called Diovan. In a short period of time this medication became the drug of choice in the treatment of Hypertension and Congestive Heart Failure. Today Diovan is one of the most prescribed medicine in the USA and European Union. Diovan combines high efficiency and safety, good tolerance, simplicity of use and lack of significant interactions. More than 45 thousands of patients took part in many clinical trials of Diovan(VALUE, Val-Syst, MARVAL, ABCD-2V, VALIANT, Val-HeFT) organized by Novartis. This in its turn made possible to investigate many Diovan effects in hypertension, diabetic nephropathy, congestive heart failure. In mentioned above trials Diovan showed ability to increase patient's lifetime and prevent the development of cardiovascular complications such as stroke, heart attack and acute heart failure. One dosage of Diovan is ussually enough to control high blood pressure within 24 hours.
Diovan doesn't require the constant dosage correction as the effect of addiction doesn't occur. It gives possibility to indicate Diovan in prolonged treatment or in lifelong therapy in patients with high blood pressure. It was established that Diovan can successfully be used in combination with thiazide diuretics and as a result increased hypotensive effect is observed.